BioSpace News Archive

Potential New Treatment Option for the Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture

Nexus Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of Busulfan Injection, the company’s AP-rated therapeutic equivalent for Busulfex® 60 mg/10 mL (6 mg/1 mL).

Innovent Biologics, Inc. announced that the first patient has been dosed in a phase III clinical trial (ORIENT-16) that is to evaluate Tyvyt®, in combination with capecitabine and oxaliplatin, as first-line treatment for patients with advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (GC or GEJ).

Ready for collaborations, the registry enables faster, more cost-effective access to research-grade RA data for better understanding, comparing, and predicting treatment outcomes

Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, subsidiary HempMeds® announced today the release of its newest cannabidiol (CBD) product Real Scientific Hemp Oil™ (RSHO™) Maximum Strength.

Organizations Join Forces to Expand Delivery of Personalized, Innovative Care Models

Financing led by Andreessen Horowitz with Participation from Section 32 and Verily

Recognized by CIOReview and FierceBiotech as One of the Best Life Sciences Solutions of 2018, VirTrial is revolutionizing the way Clinical Trials are Conducted

Founder Partners with Industry-Focused Private Equity Firm to Power Next Chapter of TRX’s Ongoing Mission as the Global Leader in Functional Training Solutions & Programming

With tissue culture micropropagation, Conception produces plantlets that are free of pathogens and have exceptional vigor, at a cost-per-plant below producers’ in-house costs.